A Biochemical Study of Fibroblast Growth Factor -23 and Phosphorus Metabolism in Adult Patients with Obstructive Renal Failure in Babylon-Iraq

Subject Areas : Journal of Chemical Health Risks

Mohammed K. Kadhim ¹ , Ban M. Shaker Al-joda ² , Mohammed R. Jood ³

1 - Department of chemistry and Biochemistry, Faculty of Medicine, Babylon University, Babel, Iraq
2 - Assistant Professor, College of Medicine, Department of Chemistry and Biochemistry, Faculty of Medicine – University of Babylon/ Babel, Iraq
3 - Professor of Urology at the Faculty of Medicine - University of Babylon/ Babel, Iraq

Received: 2021-05-01 Accepted : 2021-07-31 Published : 2021-10-01

Keywords:

References:

1. Undre S., Marks S.D., 2016. Obstructive Uropathy Pediatric Kidney Disease. pp. 1121-1133: Springer.


2. Cheungpasitporn W., Rossetti S., Friend K., Erickson S.B., Lieske J.C., 2016. Treatment effect, adherence, and safety of high fluid intake for the prevention of incident and recurrent kidney stones: a systematic review and meta-analysis. Journal of Nephrology. 29(2), 211-219.


3. Stevens S., 2018. Obstructive Kidney Disease. Nurs Clin North Am. 53(4), 569-578.


4. Dousdampanis P., Trigka K., Stefanidis I., 2020. "Obstructive Nephropathy.pp. 502-511.


5. Klahr S., 2000. The geriatric patient with obstructive uropathy. Nephrology and Geriatrics Integrated. 167-177.


6. Wolf M., 2012. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney International. 82(7), 737-747.


7. Bär L., Stournaras C., Lang F., Föller M., 2019. Regulation of fibroblast growth factor 23 (FGF 23) in health and disease. FEBS letters. 593(15), 1879-1900.


8. Murali S.K., Roschger P., Zeitz U., Klaushofer K., Andrukhova O., Erben R.G., 2016. FGF23 regulates bone mineralization in a 1, 25 (OH) 2D3 and klotho‐independent manner. Journal of Bone and Mineral Research. 31(1), 129-142.


9. Leifheit-Nestler M., Haffner D., 2018. Paracrine effects of FGF23 on the heart. Frontiers in Endocrinology. 9, 278.


10. Scialla J.J., Xie H., Rahman M., Anderson A.H., Isakova T., Ojo A., Zhang X., Nessel L., Hamano T., Grunwald J.E., 2014. Fibroblast growth factor-23 and cardiovascular events in CKD. Journal of the American Society of Nephrology. 25(2), 349-360.


11. Neyra J.A., Hu M.C., Moe O.W., 2020. Fibroblast Growth Factor 23 and αKlotho in Acute Kidney Injury: Current Status in Diagnostic and Therapeutic Applications. Nephron. 144(12), 665-672.


12. Christov M., Neyra J.A., Gupta S., Leaf D.E., 2019, January. Fibroblast growth factor 23 and klotho in AKI. In Seminars in Nephrology.  39(1), 57-75). WB Saunders.


13. Leaf D.E., Wolf M., Waikar S.S., Chase H., Christov M., Cremers S., Stern L., 2012. FGF-23 levels in patients with AKI and risk of adverse outcomes. Clinical Journal of the American Society of Nephrology. 7(8), 1217-1223.


14. Muñoz‐Castañeda J.R., Herencia C., Pendón‐Ruiz de Mier M.V., Rodriguez‐Ortiz M.E., Diaz‐Tocados J.M., Vergara N., Martínez‐Moreno J.M., Salmerón M.D., Richards W.G., Felsenfeld A., 2017. Differential regulation of renal Klotho and FGFR1 in normal and uremic rats. The FASEB Journal. 31(9), 3858-3867.


15. Rodríguez-Ortiz M.E., Díaz-Tocados J.M., Muñoz-Castañeda J.R., Herencia C., Pineda C., Martínez-Moreno J.M., Montes de Oca A., López-Baltanás R., Alcalá-Díaz J., Ortiz A., 2020. Inflammation both increases and causes resistance to FGF23 in normal and uremic rats. Clinical Science. 134(1), 15-32.


16. Rodríguez M., 2020. FGF23: Is It Another Biomarker for Phosphate–Calcium Metabolism? Advances in Therapy. 37(2), 73-79.


17. Andrukhova O., Zeitz U., Goetz R., Mohammadi M., Lanske B., Erben R.G., 2012. FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2–SGK1 signaling pathway. Bone. 51(3), 621-628.


18. Andrukhova O., Smorodchenko A., Egerbacher M., Streicher C., Zeitz U., Goetz R., Shalhoub V., Mohammadi M., Pohl E.E., Lanske B., 2014. FGF 23 promotes renal calcium reabsorption through the TRPV 5 channel. The EMBO Journal. 33(3), 229-246.


19. Mace M.L., Gravesen E., Nordholm A., Olgaard K., Lewin E., 2018. Fibroblast growth factor (FGF) 23 regulates the plasma levels of parathyroid hormone in vivo through the FGF receptor in normocalcemia, but not in hypocalcemia. Calcified tissue International. 102(1), 85-92.


20. Micarelli D., Cristi E., Taddei A.R., Della Rovere F.R., Mercanti C., Feriozzi S., 2020. A case of acute renal failure with multiple origins of the renal injury. CEN Case Reports. 9(4), 437-441.


21. Agoro R., Montagna A., Goetz R., Aligbe O., Singh G., Coe L.M., Mohammadi M., Rivella S., Sitara D., 2018. Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. The FASEB Journal. 32(7), 3752-3764.


22. Tolani M.A., Ahmed M., Nasir O., Sudi A., 2020. Obstructive uropathy and intrinsic renal disease in patients with benign prostatic obstruction: analysis of burden and associations in a university teaching hospital in Nigeria. Journal of Medicine in the Tropics. 22(2), 127.


23. Rygasiewicz K., Hryszko T., Siemiatkowski A., Brzosko S., Rydzewska-Rosolowska A., Naumnik B., 2018. C-terminal and intact FGF23 in critical illness and their associations with acute kidney injury and in-hospital mortality. Cytokine. 103, 15-19.